ALERT: Your health is top priority. We’re committed to providing reliable COVID-19 resources to keep you informed and safe.

Gadolinium Side Effects

Side effects of gadolinium-based contrast agents are often mild. The most common side effects include injection site pain, nausea, itching, rash, headaches and dizziness. Serious but rare side effects such as gadolinium toxicity and nephrogenic systemic fibrosis, or NSF, are most often seen in patients with severe kidney problems.

People who undergo an MRI scan with a gadolinium-based contrast agent, or GBCA, may experience coldness at the injection site, altered taste or the sensation known as pins and needles, depending on the brand of drug used.

A 2016 study in Magnetic Resonance Imaging found headaches, bone and nerve pain, and skin thickening were the most commonly reported reactions in patients that were presumed to have gadolinium toxicity. In the study of 42 people with symptoms, brain fog and headaches lasted for more than three months in 29 people.

Vomiting can occur with less than 1 in 100 injections, according to Inside Radiology. Between 1 and 4 in 100 will notice mild nausea or a headache.

Studies and adverse event reports submitted to the U.S. Food and Drug Administration (FDA) link GBCAs to nephrogenic systemic fibrosis, a serious condition that causes skin tightening. In the most serious cases, nephrogenic systemic fibrosis can cause thickening or scarring of the internal organs, which could lead to death. This side effect appears mostly in patients who had pre-existing kidney conditions, and has been estimated to occur in about 4 percent of patients with severe kidney disease that receive GBCAs.

New warnings from the FDA, added in 2018, say gadolinium can stay in the body for months to years after receiving these drugs during an MRI scan. It can build up in bone, brain and kidney tissue. This is known as gadolinium retention.

Did You Know?
Gadolinium may remain in the body for months or years.
Source: U.S. Food and Drug Administration


Toxicity is a side effect of GBCAs that can occur within hours after undergoing an MRI scan with one of these contrast agents. Or it can manifest years later in people who have gadolinium buildup in their bodies.

Symptoms vary from person to person. The severity ranges from mild to severe.

Symptoms include:
  • Pain in the bones or joints
  • Burning or “pins and needle” sensations in the skin
  • Brain fog
  • Headache
  • Vision or hearing changes
  • Changes to the skin, such as thickening or discoloration
  • Nausea, vomiting, or diarrhea
  • Difficulty breathing
  • Flu-like symptoms
  • Metallic taste

Causes and People at Risk

Linear GBCAs are more likely to cause toxicity than macrocyclic agents, based on their structure. These are the two types of GBCAs available in the U.S.

A 2016 study review published in Biometals suggested one linear GBCA called Omniscan caused skin lesions, skin thickening and cell swelling in rats. Scientists linked the lesions to high gadolinium concentrations in the skin, liver and femur.

Another study published in 2004 in Investigational Radiology showed Omniscan, a linear GBCA, left 2.5 times more gadolinium in human bone than ProHance, a macrocyclic agent.

Linear gadolinium-based contrast agents vs macrocyclic gadolinium-based contrast agents.
Source: Biometals

People who have multiple MRIs with GBCAs potentially increase the risk for toxicity.

Other patients at greater risk of these problems are pregnant women, people who have kidney problems, people with conditions that cause inflammation, or children, according to the FDA.

Testing and Treatment

Few doctors understand this type of toxicity, and there are few methods to test for it. The main tests are urine and blood tests. However, according to an article in Radiology in 2018, normal ranges have not been defined for each GBCA, and these methods need to be tested and standardized before they can be used as a reliable technique for monitoring gadolinium levels.

Illustration of how chelating close bonds of gadolinium.

Chelation is a treatment that can be used to remove toxic levels of heavy metals from the body, although it has not been well studied as a treatment for gadolinium toxicity. Chelation is a process where doctors administer chelating agents to patients. These agents bind gadolinium and remove it from the body through the kidneys.

Health providers may administer chelating agents through an IV, with a pill, as a suppository under the tongue or through a rectal suppository.

Because this type of toxicity may cause pain in the bones, skin or joints, some people use some type of pain relieving medication.

Some patients may respond to treatment involving immune system modulation, although this proposed benefit appears to be theoretical and has not been tested in patients. Immune modulation is using drugs or other agents to weaken or strengthen the immune system.

Nephrogenic Systemic Fibrosis (NSF)

Nephrogenic Systemic Fibrosis (NSF) is a disease that causes hardening and thickening of the skin and internal organs, which could potentially lead to death. According to the Cleveland Clinic, most, if not all, cases are caused by exposure to GBCAs.

Patients who developed the condition who had not been exposed to a GBCA in an MRI were exposed to gadolinium in another way, such as another test, surgery, an injury or an infection. Although the exact mechanism for how the chemical element causes the condition is not known, the risk increases with use of linear gadolinium, and as more gadolinium is administered overall.

Researchers consider the disease to be a rare but serious side effect of GBCAs. These drugs carry a boxed warning that says people with kidney problems are at risk for the disease.

About 4 percent of people with serious kidney problems develop the condition after exposure to the chemical element. At least 30 percent of cases are expected to result in death.

The FDA first alerted the public about the link between GBCAs and NSF in 2006. The agency advises against using GBCAs in certain patients with acute or chronic kidney problems.

Researchers have not reported NSF in patients with normal kidney function after receiving GBCAs.

About 4 percent of patients with severe renal insufficiency following exposure to GBCAs develop NSF. Close to 31 percent of NSF cases end in death.
Source: Study published in American Family Physician

Gadolinium Deposition Disease (GDD)

GDD is a relatively newly proposed condition, and it resembles NSF. However, GDD specifically occurs in people with normal kidney function.

Scientists think people who get GDD have a genetic abnormality that makes it difficult for their bodies to get rid of heavy metals; however, GDD is still being studied and agencies such as the FDA report that gadolinium deposition has not been directly linked to negative outcomes in patients with normal kidney function.

People who had normal or near-normal kidney function when they were injected with a gadolinium-based contrast agent but then developed toxicity symptoms are suing the drugs’ makers.

Gadolinium Vial
Gadolinium Side Effects
  1. Gadolinium toxicity Symptoms include pain in the skin, bones, joints or head
  2. Gadolinium Deposition Disease (GDD) Can happen when gadolinium remains in the body for months or years
  3. Nephrogenic systemic fibrosis (NSF) Causes the skin and internal organs to harden
  4. Less serious side effects nausea, headache and dizziness

Please seek the advice of a medical professional before making health care decisions.

Michelle Llamas, Senior Content Writer
Written By Michelle Llamas Senior Writer

Michelle Llamas has been writing articles and producing podcasts about drugs, medical devices and the FDA for nearly a decade. She focuses on various medical conditions, health policy, COVID-19, LGBTQ health, mental health and women’s health issues. Michelle collaborates with experts, including board-certified doctors, patients and advocates, to provide trusted health information to the public. Some of her qualifications include:

  • Member of American Medical Writers Association (AMWA) and former Engage Committee and Membership Committee member
  • Centers for Disease Control and Prevention (CDC) Health Literacy certificates
  • Original works published or cited in The Lancet, British Journal of Clinical Pharmacology and the Journal for Palliative Medicine
Edited By
Emily Miller
Emily Miller Managing Editor
Medically Reviewed By

24 Cited Research Articles writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.

  1. Cleveland Clinic. (n.d.). Nephrogenic Systemic Fibrosis (NSF). Retrieved from
  2. Rogosnitzky, M & Branch, S. (2016). Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Retrieved from
  3. Ramalho, J. et al. (2016, December). Gadolinium toxicity and treatment. Retrieved from
  4. Robert, P. et al. (2016, February). Linear Gadolinium-Based Contrast Agents Are Associated With Brain Gadolinium Retention in Healthy Rats. Retrieved from
  5. Burke L.M. et al. (2016, October). Self-reported gadolinium toxicity: A survey of patients with chronic symptoms. Magnetic Resonance Imaging. Retrieved from
  6. Mayo Medical Laboratories. (n.d.). Test ID: GDU, Gadolinium 24 Hour, Urine. Retrieved from
  7. Scheinfeld, N.S. (2018, May 22). Nephrogenic System Fibrosis. Retrieved from
  8. Shrivastava, V. (2016, November 21). Extracorporeal Photopheresis. Retrieved from
  9. Ferris, N. and Goergen, S. (2017, July 26). Gadolinium Contrast Medium (MRI Contrast agents). Inside Radiology. Retrieved from
  10. U.S. Food and Drug Administration. (2018, May 16). FDA Drug Safety Communication: FDA warns that gadolinium-based contract agents (GBCAs) are retained in the body; requires new class warnings. U.S. Department of Health and Human Services. Retrieved from
  11. Skandhan, A.K.P. and Gaillard, F. et al. (n.d.). Nephrogenic systemic fibrosis. Radiopaedia. Retrieved from
  12. Schlaudecker, J.D. and Bernheisel, C.R. (2009, October 1). Gadolinium-Associated Nephrogenic Systemic Fibrosis. American Family Physician. Retrieved from
  13. U.S. National Library of Medicine. (2018, February 27). Anaphylaxis. Medline Plus. NIH. Retrieved from
  14. U.S. Food and Drug Administration. (2010, September 9). FDA Drug Safety Communication: New warnings for using gadolinium-based contrast agents in patients with kidney dysfunction. U.S. Department of Health and Human Services. Retrieved from
  15. (2018, July 23). Contrast Materials. Retrieved from
  16. Hess, C. et al. (2017, November 12). MRI with Contrast (Gadolinium-Containing) Policy. UCSF Department of Radiology & Biomedical Imaging. Retrieved from
  17. Semelka, R.C. et al. (2016, August 13). Gadolinium deposition disease: Initial description of a disease that has been around for a while. U.S. National Library of Medicine. Retrieved from
  18. Semelka, R.C. et al. (2016, December). Gadolinium deposition disease: Initial description of a disease that has been around for a while. Magnetic Resonance Imaging. Retrieved from
  19. Scheinfeld, N.S. (2018, May 22). Nephrogenic Systemic Fibrosis Treatment & Management. Retrieved from
  20. Gibby, W.A. (2004, March). Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Investigative Radiology. Retrieved from
  21. Rees, J.A. et al. (2018, March 13). Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents. Scientific Reports. Retrieved from
  22. Khawaja, A.Z. et al. (2015, August 8). Revisiting the risks of MRI with gadolinium based contrast agents—review of literature and guidelines. Retrieved from
  23. McDonald R.J. et al. (2018, November). Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates. Radiology. Retrieved from
  24. Ramalho, J. et al. (2016, December). Gadolinium toxicity and treatment. Magnetic resonance imaging. Retrieved from
View All Sources
Who Am I Calling?

Calling this number connects you with one of Drugwatch's trusted legal partners. A law firm representative will review your case for free.

Drugwatch's trusted legal partners support the organization’s mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.

(888) 645-1617